 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...244245246247248249250251252253254...266267» |
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Adverse events: Yervoy Pregnancy Surveillance Study (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=10, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 9, 2016
P1/2, N=1150, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=1500 --> 1150
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Tumor mutational burden, IO biomarker: CheckMate 568: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 9, 2016
P2, N=590, Recruiting, Sponsor: Bristol-Myers Squibb
N=1500 --> 1150 N=340 --> 590
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Nov 9, 2016
P3, N=870, Recruiting, Sponsor: Bristol-Myers Squibb
N=340 --> 590 Trial primary completion date: Mar 2019 --> Jul 2019
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CA209-742: A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (clinicaltrials.gov) - Nov 9, 2016
P3, N=102, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2019 --> Jul 2019 Not yet recruiting --> Recruiting
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Nov 8, 2016
P1, N=470, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=88 --> 470
- |||| Opdivo (nivolumab) / BMS
Enrollment open: TITAN-RCC: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 8, 2016
P2, N=200, Recruiting, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Recruiting | N=88 --> 470 Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 3, 2016
P1/2, N=1500, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=1100 --> 1500
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, PD(L)-1 Biomarker: Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=1100 --> 1500 Recruiting --> Active, not recruiting
- | Neo Vax (NEO-PV-01) / BioNTech, Yervoy (ipilimumab) / BMS
New P1 trial, Tumor-specific neoantigens: NeoVax Plus Ipilimumab in Renal Cell Carcinoma (clinicaltrials.gov) - Nov 1, 2016
P1, N=20, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CA209-742: A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (clinicaltrials.gov) - Oct 28, 2016
P3, N=102, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2020 --> Sep 2017
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: CheckMate 722: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (clinicaltrials.gov) - Oct 28, 2016
P3, N=465, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2020 --> Sep 2017 Not yet recruiting --> Recruiting
- || Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Oct 26, 2016
P1, N=88, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=470 --> 88
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (clinicaltrials.gov) - Oct 26, 2016
P1/2, N=66, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | N=470 --> 88 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Oct 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MAPS2: Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (clinicaltrials.gov) - Oct 25, 2016
P2, N=125, Active, not recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> May 2017
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New trial, Monotherapy: Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=323, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Monotherapy, Metastases: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (clinicaltrials.gov) - Oct 20, 2016
P1, N=48, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> May 2017 Trial primary completion date: Dec 2017 --> Jun 2019
- |||| Enrollment open, PD(L)-1 Biomarker, IO biomarker: Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (clinicaltrials.gov) - Oct 20, 2016
P2, N=230, Recruiting, Sponsor: Fondazione Melanoma Onlus
Trial primary completion date: Dec 2017 --> Jun 2019 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 19, 2016
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CA209-742: A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (clinicaltrials.gov) - Oct 18, 2016
P3, N=102, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Sep 2017 --> Oct 2020
- ||||| New P2 trial: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 16, 2016
P2, N=910, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Oct 13, 2016
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Oct 2020 Recruiting --> Active, not recruiting
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Oct 13, 2016
P3, N=870, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 12, 2016
P2, N=39, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- varlilumab (CDX 1127) / Celldex, rasdegafusp alfa (CDX-1401) / Celldex
Trial primary completion date, Combination therapy, Metastases: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Oct 12, 2016
P2, N=9, Active, not recruiting, Sponsor: Celldex Therapeutics
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Jan 2017
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date: CheckMate 817: An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (clinicaltrials.gov) - Oct 11, 2016
P3b/4, N=1500, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2018 --> Jan 2017 N=500 --> 1500 | Trial primary completion date: Oct 2020 --> Sep 2018
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=500 --> 1500 | Trial primary completion date: Oct 2020 --> Sep 2018 Trial primary completion date: Nov 2017 --> Nov 2018
- | Imlygic (talimogene laherparepvec) / Amgen
Phase classification: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Oct 7, 2016
P1b/2, N=217, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Nov 2017 --> Nov 2018 Phase classification: P1/2 --> P1b/2
- || Skyclarys (omaveloxolone) / Biogen
Phase classification, Trial primary completion date: RTA 408 Capsules in Patients With Melanoma - REVEAL (clinicaltrials.gov) - Oct 6, 2016
P1b/2, N=84, Recruiting, Sponsor: Reata Pharmaceuticals, Inc.
Phase classification: P1/2 --> P1b/2 Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Mar 2017 --> Jun 2017
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker, IO biomarker: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (clinicaltrials.gov) - Oct 5, 2016
P2, N=60, Not yet recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: OpACIN: Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (clinicaltrials.gov) - Oct 4, 2016
P1, N=20, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- varlilumab (CDX 1127) / Celldex, rasdegafusp alfa (CDX-1401) / Celldex
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Oct 3, 2016
P2, N=9, Active, not recruiting, Sponsor: Celldex Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=100 --> 9
- Yervoy (ipilimumab) / BMS
Phase classification, Monotherapy: Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (clinicaltrials.gov) - Sep 30, 2016
P1b, N=12, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=100 --> 9 Phase classification: P1 --> P1b
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (clinicaltrials.gov) - Sep 30, 2016
P2, N=100, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1 --> P1b Initiation date: Jul 2016 --> Nov 2016 | Trial primary completion date: May 2018 --> Oct 2018
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CheckMate 817: An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (clinicaltrials.gov) - Sep 30, 2016
P3b/4, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jul 2016 --> Nov 2016 | Trial primary completion date: May 2018 --> Oct 2018 Not yet recruiting --> Recruiting
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: CheckMate 714: Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Sep 30, 2016
P2, N=315, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Sep 29, 2016
P1/2, N=352, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Oct 2020
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Sep 29, 2016
P2, N=40, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- ||||| Opdivo (nivolumab) / BMS
New P2 trial: TITAN-RCC: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 28, 2016
P2, N=200, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: NCI-2016-00661: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 27, 2016
P1/2, N=80, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2016 --> Oct 2020 Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020
- Yervoy (ipilimumab) / BMS
Phase classification: Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (clinicaltrials.gov) - Sep 26, 2016
P1, N=89, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020 Phase classification: P2 --> P1
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Tumor mutational burden, IO biomarker: CheckMate 568: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 26, 2016
P2, N=340, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P2 --> P1 N=170 --> 340
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
N=170 --> 340 N=199 --> 500
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker: CheckMate 722: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (clinicaltrials.gov) - Sep 26, 2016
P3, N=465, Not yet recruiting, Sponsor: Bristol-Myers Squibb
N=199 --> 500 Trial primary completion date: Apr 2019 --> Jul 2019
- | Yervoy (ipilimumab) / BMS
Trial completion: Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (clinicaltrials.gov) - Sep 25, 2016
P1, N=89, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Apr 2019 --> Jul 2019 Recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Enrollment closed, Tumor-infiltrating lymphocyte, Surgery, Pre-surgery: TOP1201 IPI: Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 23, 2016
P2, N=30, Active, not recruiting, Sponsor: Duke University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Sep 22, 2016
P1/2, N=18, Not yet recruiting, Sponsor: David Minor, MD
- | Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Sep 22, 2016
P2, N=21, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=64 --> 21
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=22, Active, not recruiting, Sponsor: Stanford University
N=64 --> 21 Recruiting --> Active, not recruiting
- || Yervoy (ipilimumab) / BMS
Trial primary completion date: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na (clinicaltrials.gov) - Sep 20, 2016
P1/2, N=57, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017